Podcasts about responses

We want to work with YOU! 15 Minute Free Consultation  Start healing now! Set up a Coaching Session In this episode of Mr. and Mrs. Therapy podcast, the hosts delve into the phenomenon of experiencing a racing, jittery feeling and interpreting it as either excitement or anxiety. They discuss the physiological responses driven by the sympathetic nervous system and provide a self-check tool to help listeners distinguish between excitement and fear. The episode covers the role of perspective and inputs in shaping these feelings and offers techniques to reframe negative thoughts, including the concept of neuroplastic shift. The hosts conclude with a five-question self-check tool to help listeners rework their anxiety into excitement. 00:00 Introduction to the Podcast 00:07 Understanding the Racing Jittery Feeling 00:50 The Science Behind the Physiological Surge 01:36 Interpreting Excitement vs. Anxiety 03:19 The Role of Perspective and Inputs 05:11 Side-by-Side Comparison: Excitement vs. Anxiety 07:33 Reframing Anxiety into Excitement 10:17 Five Question Self-Check Tool 12:04 Conclusion and Final Thoughts [Remember, our podcast is here to spark conversations and offer insights. Join our community on our Mr. and Mrs. Therapy Podcast Group, share your experiences at podcast@mrandmrstherapy.com, and if you're seeking more personalized advice, consider booking your free coaching consultation. Please note, this podcast is for informational purposes only and is not intended to provide diagnosis or treatment.] {Disclaimer: This podcast is for informational purposes only and is not intended to provide diagnosis or treatment. For personalized support, please seek professional help or call the National Suicide Hotline at 988 if you or someone you know is contemplating suicide or needs emotional support.}

What did you think of today's d-bag? Dad's are fighting.

The sudden termination of US overseas funding jolted AIDS programs in countries hardest hit by the epidemic. Yet the leaders of national AIDS programs had already been preparing for the day when donor funding ended. The HIV Leadership Forum, a community of practice of Directors General of National AIDS Councils from around the world has recently published a report setting out steps on how resilient and sustainable national programs can be achieved.   Ben is joined by Dr Nduku Kilonzo, Chair of the UNAIDS Global HIV Prevention Coalition, and Dr. Thembisile Xulu, CEO of the South African National AIDS Council, to explore the strategies and challenges in the post-donor era for HIV/AIDS prevention and treatment. Key topics include the importance of sustainability, integrating HIV programs into broader health systems, and rethinking donor-country partnerships. Both experts offer valuable insights into how African countries are navigating the reduction in international funding while striving to meet their health goals. 00:00 Introduction and Episode Overview 01:11 Meet Dr. Nduku Kilonzo 01:38 Key Findings from the International Aid Society Scientific Conference 03:09 The HIV Leadership Forum and Sustainability Report 05:11 Challenges and Lessons in HIV Prevention 17:42 Interview with Dr. Thembisile Xulu 21:16 South Africa's Response to Funding Cuts 32:03 The Future of HIV Programs and Donor Relationships 47:49 Concluding Thoughts and Reflections 53:07 Closing Remarks and Call to Action  

Doug, Brad and David in the studio at the same time. Responses to the death of John MacArthur SWAT Training Day with Virgil Walker Doug has left the building Continuing The Nashville Statement Replay of Phil Johnson interview with Doug ------------------ Various passages __________________ 5 Core Values of SWAT 1. God's Word 2. Prayer 3. Evangelism 4. Discipleship 5. Community ------------------ https://swatradio.com/ SWAT - Spiritual Warriors Advancing Truth Call us Toll-Free at: +1-844-777-7928 Email Us a Question: ask@swatradio.com FIND A SWAT MEETING Brown Family YMCA 170 Landrum Lane Ponte Vedra Beach, FL 32082 Wed. 6:30-7:30 am IHOP 3250 Hodges Blvd Jacksonville, FL 32224 Wed. Night 7-8 pm Salem Centre 7235 Bonneval Rd Jacksonville, FL Wed. 12:00-1:00 pm Jumping Jax House of Food 10131 San Jose Blvd #12 Jacksonville, FL Thursday 6:30-7:30 am The Village Inn 900 Ponce De Leon Blvd St. Augustine, FL Friday 9:00-10:30 am Woodmen Valley Chapel - Woodmen Heights Campus 8292 Woodman Valley View Colorado Springs CO 80908 Thursdays 8-9:15 pm

BUFFALO, NY - July 16, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on July 9, 2025, titled “A novel anti-human CD25 mAb with preferential reactivity to activated T regulatory cells depletes them from the tumor microenvironment.” In this study, researchers from the National Institute of Allergy and Infectious Diseases, led by first author Maja Buszko and corresponding author Ethan M. Shevach, discovered a new monoclonal antibody that selectively targets a subset of immune cells called regulatory T cells (Tregs). These cells, while normally important for preventing autoimmunity, also can block the body's ability to fight cancer by suppressing anti-tumor immune responses. This discovery could lead to novel cancer therapies that strengthen the immune system's capacity to attack tumors. The researchers identified an anti-CD25 monoclonal antibody with several atypical properties and named it 2B010. To evaluate its effects, they used humanized mice, laboratory mice that are engineered to carry human immune cells, to closely mimic how human immune systems respond to cancer. The treatment of these mouse models with 2B010 significantly decreased the number of Tregs in tumors and boosted the activity of CD8+ T cells, which are essential for killing cancer cells. Importantly, 2B010 worked without disrupting other key immune functions. Unlike traditional Anti-CD25 antibodies, it did not interfere with interleukin-2 (IL-2) signaling, which is essential for the growth and activity of effector T cells that fight cancer. “2B010 also had no effect on IL-2 induced STAT5 phosphorylation or CD4+ T cell proliferation in vitro while both were blocked by Clone D1 further supporting the view that 2B010 does not recognize the IL-2 binding site.” This finding is especially significant because high levels of Tregs in tumors are associated with poor outcomes in many cancers. By specifically removing these cells, 2B010 may help overcome one of the main barriers to current immunotherapy approaches. Its ability to preserve IL-2 signaling could also make it safer and more effective when used alone or in combination with existing therapies such as immune checkpoint inhibitors. While the 2B010 antibody showed strong effects in reducing Tregs and boosting immune cell activity, the study did not observe changes in tumor size in these models. Researchers suggest this may be due to limitations in the preclinical systems used, such as the lack of tumor-specific T cells in humanized mice. Nevertheless, these findings demonstrate that 2B010 has a unique mechanism of action that could complement other cancer immunotherapies in future clinical trials. In conclusion, the development of 2B010 is a promising step toward selectively disrupting the immune suppressive environment in tumors. As researchers continue to refine and test this antibody, it could become a powerful tool for enhancing the effectiveness of cancer treatments and improving outcomes for patients. DOI - https://doi.org/10.18632/oncotarget.28752 Correspondence to - Ethan M. Shevach - eshevach@Niaid.NIH.gov Video short - https://www.youtube.com/watch?v=2NJcGsI7WXA Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28752 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, Treg, CD25, TME, mAb, GVHD To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Watch the YouTube version of this episode HEREAre you a law firm owner looking for advice on how to make your firm more lucrative? In this episode of the Maximum Lawyer Podcast, Tyson interviews Ted DeBettencourt, a JD/MBA and a business owner. Ted shares his journey from Martha's Vineyard to legal tech entrepreneurship, discussing the island's unique culture and his transition from law to business. To run a successful law firm, it is important that certain processes are in place and run efficiently to turn a profit. An important thing to implement is to ensure there are more staff over auto responders and AI for Local Service Ads (LSA). LSA's will rank firms based on response times and this can affect how people perceive your firm at the first click. If your response time is slow, most people will not call you for help. Using real people to answer leads and call prospective clients will ensure you get off on the right foot with people who are looking for legal support.Ted and Tyson chat about the three most important marketing metrics for a successful law firm. The first metric is wanted leads. It is important to know how many leads are actually wanted, in which a firm will be interested in taking on. The second metric is signed rates. Out of the wanted leads, how many of them were signed on as actual cases for the firm. This will determine how successful a firm is when it comes to the number of cases that are taken on and it can show value. The third metric is average case value. This can be determined by how much a firm makes in a year based on the type of cases. Ultimately, the average case value will let someone know how successful a firm really is.Listen in to learn more!05:25 Google Local Services Ads (LSA) and Lead Response06:49 Manual vs. Automated Lead Response07:46 Importance of Fast Lead Response09:20 AI vs. Human Chat: Present and Future10:37 Human Connection in the Age of AI11:26 Regulations and Human-Only Policies23:14 What Sets Successful Law Firms Apart25:54 Key Marketing Metrics for Law FirmsTune in to today's episode and checkout the full show notes here. Connect with Ted at JuvoLeads:Website Linkedin 

Send us a textActs 17:24-34The God who made the world and everything in it, being Lord of heaven and earth, does not live in temples made by man, nor is he served by human hands, as though he needed anything, since he himself gives to all mankind life and breath and everything. And he made from one man every nation of mankind to live on all the face of the earth, having determined allotted periods and the boundaries of their dwelling place, that they should seek God, and perhaps feel their way toward him and find him. Yet he is actually not far from each one of us, for“‘In him we live and move and have our being';as even some of your own poets have said,“‘For we are indeed his offspring.'Being then God's offspring, we ought not to think that the divine being is like gold or silver or stone, an image formed by the art and imagination of man. The times of ignorance God overlooked, but now he commands all people everywhere to repent, because he has fixed a day on which he will judge the world in righteousness by a man whom he has appointed; and of this he has given assurance to all by raising him from the dead.”Now when they heard of the resurrection of the dead, some mocked. But others said, “We will hear you again about this.” So Paul went out from their midst. But some men joined him and believed, among whom also were Dionysius the Areopagite and a woman named Damaris and others with them.Support the show

ReferencesFront Immunol. 2017 Jun 9;8:643JAMA. 2021;325(16):1640-1649Journal of Hepatology 2012 56, 704-713DOI:(10.1016/j.Annual Review of Food Science and Technology.2022.  Volume 13:263-286Annual Review of Pathological Mechanisms of Disease 2010. 5:99-118.Nature.2013 Jul 4;499(7456):97-101 Nature Reviews Gastroenterology and Hepatology 26 April 2019Cell Metabolism 2019. [29] 4:886-900Lamm, R. 1972. "While the City Sleeps" Chicago Vhttps://music.youtube.com/watch?v=qCrgrGsBlr0&si=oGMvJDfCrd2BU7_ICetera and Seraphine . "Lowdown" Chicago IIIhttps://music.youtube.com/watch?v=6LlZCBbeZTk&si=DrSyAp9lCzhZyqfWLamm, R. 1969. "Questions 67 and 68" CTAhttps://music.youtube.com/watch?v=0TKaFqhmmg4&si=_W-MMatKBBQ0cBF9

Have you ever wondered what is so special about God? Why is he worthy of praise? Psalm 135 details his power and sovereignty, and three "Rs" to help us understand the scripture's framework: The REASONS God's name is worthy of praise, the RESPONSES we can have, and the RESULTS of our responses. ---Join us for service online or in-person in Grand Rapids every Sunday at 9AM & 10:30AM. Decided to follow Jesus? We would love to help you figure out what's next! Let us know at https://bit.ly/TLC-i-decidedStay Connected!Website: http://localchurchgr.orgLocal Church Facebook: http://facebook.com/localchurchgrLocal Church Instagram: http://instagram.com/localchurchgrWeekly Email Newsletter: https://bit.ly/trendingatTLCVisit & What to Expect: http://localchurchgr.org/expectEvents: http://my.localchurchgr.org/events If you would like to support The Local Church GR's ministry and help us continue reaching people in the Grand Rapids area, click here: https://localchurchgr.org/giveNeed prayer? Please let us know! - https://localchurchgr.org/care

ReferencesThe Journal of Nutritional Biochemistry 2016.Volume 34, pages 1-7Immunologic Research,2020. 1559-0755,Feb, Vol. 68, Issue 1Cell Metabolism 2019. [29] 4:886-900Guerra, DJ.2025. Unpublished LecturesAnderson and Howe. 1971. "Roundabout" Yes.https://music.youtube.com/watch?v=pk3HBb0mh5Q&si=dO7xDgnAVqNl8Yv6Davis, T. 1971 "Your Saving Grace" Steve Miller Bandhttps://music.youtube.com/watch?v=RBJ6teB2IXw&si=etBGUDK87GprtnlrLennon/McCartney 1967. "She's Leaving Home" Beatles SPLHCB.https://music.youtube.com/watch?v=VaBPY78D88g&si=9upPJq5KC_jBDQI0Lennon/McCartney. 1966. "She Said" Revolver, lp Beatleshttps://music.youtube.com/watch?v=rLzfo59AdEc&si=r-AiTLLNsphoME0y

Sun 6PM

REFERENCESFront Immunol.2019; 10: 1064.ASN Neuro. 2024 Nov 5;16(1):2404367.Int J Mol Sci. 2024 Apr 10;25(8):4199Page/Jones/Plant 1969. "Since I've Been Loving You" LZ III lp.https://open.spotify.com/track/1SDiiE3v2z89VxC3aVRKHQ?si=530d2dcc304f4199Lennon/McCartney, 1964. "I Don't Want to Spoil the Party"https://open.spotify.com/track/3kQDIa85ZK8cKVn72NfBnl?si=be68c3abca6341d8Lennon/McCartney 1967. "A Day in the Life" Sgt Pepper's LHCB. lp.https://open.spotify.com/track/0hKRSZhUGEhKU6aNSPBACZ?si=8589b727398f4fbbBiber, H.I.F. 1676. "Passacaglia in G Minor. Violin sonatahttps://open.spotify.com/track/2PvqhaYNHP4zHQynKeook4?si=479490bfb34c4c2d

ReferencesMol Cancer Ther. 2018 Jan; 17(1): 50–59 J Neuroinflammation. 2019; 16: 236. Cell Host Microbe. 2016 Feb 10; 19(2): 181–193Nat Rev Microbiol. 2009 Feb; 7(2): 99–109.Cells.2020 Feb 5;9(2).Biochimica et Biophysica Acta (BBA) - Biomembranes. 2016.Volume 1858, Issue 11, November Pages 2681-2688Nat Immunol. 2024 Apr 8;25(5):778–789. Dylan, B. 1975. "Tangled up in Blue"https://music.youtube.com/playlist?list=OLAK5uy_nHWCTvQI-G4uNRNvC0AjQr9hVXG54TeSU&si=xOVhlpdBm_ygXirlMcQuinn 1971. "Pale Blue" Byrdmaniax l phttps://youtu.be/Mh3J7GqrdzY?si=UtahiK75LoZhQLe7Baker, G. 1967. "Blue Condition" Cream Disraeli Gears lp.https://youtu.be/bOAkjNX1FDI?si=3q_FcsfvWTH95RyK

A couple of weeks back, the New York Times released an expansive project, with a focus on determining the best films released in the 21st century. Having polled 500 people in the film and entertainment industry, asking each person about their top 10 favorites, they released many of the topline results. In a separate ask to its readers, over 200,000 people contributed their ballots. Both lists included similar films, and notably held Bong Joon-ho’s Parasite as it’s consensus number 1 pick. This week on FilmWeek, Christy Lemire and Tim Cogshell stick with us to discuss their thoughts and reactions on the ‘best films of the 21st century’ lists. We’re also joined by New York Times pop culture reporter and awards season columnist, Kyle Buchanan, to discuss the New York Times’ project. Visit www.preppi.com/LAist to receive a FREE Preppi Emergency Kit (with any purchase over $100) and be prepared for the next wildfire, earthquake or emergency!

How many times do you actually attempt to reach out to a prospect before you give up? On the Sales Gravy Podcast, Jessica Stokes calls out a common sales reality when prospecting: “We all know the average salesperson typically stops after three, maybe four attempts before moving on. We assume they're not interested. We want to find a juicier lead.” This common behavior defines The 3-Call Fallacy—the flawed belief that if someone doesn't respond after a few tries, they're not interested. It's where you probably tap out and tell yourself you've done enough. You haven't. Persistence is key.  Why Salespeople Quit Prospecting Too Early The premature retreat from prospecting isn't about laziness; it's rooted in fundamental misconceptions and fear. The Fear of Being Annoying The most common excuse? “I don't want to be a pest.”  You leave a voicemail, send an email, maybe try LinkedIn, and then you back off. You tell yourself you're giving them space. But your prospect doesn't remember you. When you're looking at your CRM thinking, "This is my sixth attempt—I'm going to tick this guy off," your prospect likely has no idea who you are. To them, today's call feels like the first time you've reached out. The Momentum Killer Spacing out your touchpoints destroys any traction you might have built. Waiting a week—or worse, a month—between messages forces you to restart every time. That familiar name? Forgotten. That compelling message? Gone. Momentum is built with consistency. Familiarity breeds trust, but only if you stay in front of them long enough to become familiar. The 4 Steps of Building a Fanatical Prospecting Sequence The fix? Being fanatical about sequencing.  It's about consistent, well-timed, multi-channel outreach that keeps your message fresh and front of mind. Stay Consistent: Don't let more than a few days pass between touchpoints. Regular rhythm creates recall. Think of it like a steady drumbeat—not a one-time boom. Use Multiple Channels: Your prospect may ignore emails but answer LinkedIn. Or they may screen unknown numbers but reply to a personalized video. Use all the tools available: Phone calls Emails LinkedIn messages Video messages Direct mail (for high-value prospects) Track Your True Attempt Rate: Most reps overestimate their persistence. Implement a rigorous tracking system, whether in your CRM or a simple spreadsheet, to log every single touchpoint. Reframe Your Mindset: You're not bothering people—you're offering help. If you believe in your product and know it can solve their problems, persistent outreach is a service, not a nuisance. The Prospecting Challenge Ready to put this into action? Take 20-50 leads and run a sequence over the next 30-45 days. Make contact attempts every few days using multiple channels. Track your progress. You'll likely discover: Responses after 8, 10, even 12 attempts. Prospects saying things like "I'm glad you reached out again" or "I was thinking about calling you back." Booked appointments you never would have gotten with the traditional 3-call approach. 3 Common Personal Objections (And Why They're Wrong) This is where self-sabotage shows up. Let's break down the common excuses: "I don't want to be annoying." Your prospect deleted your voicemail in 10 seconds. They're not sitting there with a map of all your attempts, getting angrier with each one. "If they were interested, they would have called back." People are busy. Interest doesn't always translate to immediate action.  "I need to focus on warmer leads." Every lead starts cold. The difference between a cold lead and a warm lead is often just consistent, value-driven follow-up. You make them warm. The Discipline Factor: Every Attempt Counts Just like you can't run a 10K after one day of training, you can't expect immediate results from prospecting. It's a cumulative effort that builds momentum over time.

Send us a text*DISCUSSION TOPICS*Robin has her own Barbie???Responses to JJ's announcement!Beyoncé Cowboy Carter artist series!Alex Breanne Corporation update!Cody is a game show judge!Amazon Prime Day Sales! What we get?Echelon adds Conversational Al to their app!Selena announces her pregnancy!Christene D'Ercole is writing a book!Class Recommendations!

Are you living life on your terms—or just checking the boxes of what you're “supposed” to do?Do you feel like you're sacrificing your family life balance just to keep up with society's expectations?In this episode, we unpack the bold decisions we made to opt out of the “normal” path—traditional jobs, mainstream schooling, and cultural pressure—and how those sacrifices led to a stronger, happier, and more united family.We're not promoting selfishness. We're advocating for intentionality. For living deliberately. For creating a family culture that nurtures emotional health, purpose, and joy.We talk about the hard choices, the personal growth it required, the sacrifices we made—and why we'd make them all over again.Whether you're a parent wondering if there's another way… or already on the path of designing your own extraordinary life… this episode will inspire you to ask better questions and bravely pursue the life you really want.

ReferencesCell Metabolism 2024. volume 36, Issue 4, 2 April : 839-856.e8Winwood/Davis. 1966 "Giimme Some Lovin" Spencer Davis Group.https://music.youtube.com/watch?v=BuQ3PaFyb9A&si=yAERzThIMPra_Ct1Cochran and Capehart. 1958. "Summertime Blues" The Who Live at Leeds lp.https://music.youtube.com/watch?v=ovHs-psC9F4&si=zLwITLtjW0aCwKPAVivaldi, A 1717-1718. "Summer" Violin Concerto. Marie Samuelson. No. 2 in G minor, Op. 8, RV 315,https://music.youtube.com/watch?v=g65oWFMSoK0&si=jw6PDRYCagn-B4fC

learn 10 responses to the question "How are you?"

George and Louise break down the hot topics of the day, including:AI Scribes now regulated as medical devices in the UK - all pilots must cease until MHRA approval UK Government announces £10 billion digital health investment and AI Early Warning System NHS 10-Year "Fit to the Future" Plan - three major shifts including analogue to digital transformation Cybersecurity failures at WA's PathWest and UK's Synnovis directly impacting patient safety?Positive AI developments: FDA approves breast cancer risk prediction tool, Australian chemotherapy dosing AIHow does Australia go about integrating 300,000+ allied health professionals into the national digital health strategy? That topic and more are covered in the chat with our guest Anita Hobson-Powell, the inaugural Chief Allied Health Officer at the Australian Government Department of Health, Disability and Ageing.Connect with Anita on LinkedInResources:NHS 10 year health plan for England. Fit to the Future LinkNational Allied Health Digital Uplift. Responses due 20 July LinkHealth Connect Australia Strategy, Architecture and Roadmap to enable health information exchange LinkANU Study on the Future of Digital Health EOI LinkVisit Pulse+IT.news to subscribe to breaking digital news, weekly newsletters and a rich treasure trove of archival material. People in the know, get their news from Pulse+IT – Your leading voice in digital health news.Follow us on LinkedIn Louise | George | Pulse+ITFollow us on BlueSky Louise | George | Pulse+ITSend us your questions pulsepod@pulseit.newsProduction by Octopod Productions | Ivan Juric

What if the blueprint for a more beautiful world is already within you? Jack explores how trust, joy, and imagination awaken transformation—from the inside out.Join the Year of Awakening with Jack Kornfield for monthly livestream Q&A hangs with Jack, and weekly lessons and reflections to keep your year focused on awakening. Use code AWAKEN50 for 50% off entry.“In the chrysalis, as the caterpillar imagines itself into the butterfly, there's a message: trust that transformation is possible. Not only is it possible—but from the heart, you can help shape it. You can make a difference.” – Jack KornfieldIn this episode, Jack mindfully explores:What brings us joy in this life?Trust, morals, justice, and taking the long viewEnlightenment and cultivating a trusting heartThe imaginal cells of the butterflyHow your voice, joy, imagination, and trust can truly make a differenceStories on trust, love, and making a differenceMindful presence and the Awakened Heart Sangha/Satsang, community, and helping each otherImagining a beautiful new world togetherFeeling yourself as a playful child of the spiritSpelunking the great mystery of life and the universeAdding your make-weight of hope to the worldAllen Ginsberg's poem HowlBringing our joy, love, tenderness and compassion to the worldThe big questions: how to hold suffering, and those causing sufferingThe power of protest, standing up, letting go of fear, and embracing the strength of joyQuestions and Responses on how to navigate modern times skillfully and joyfully with trust, balance, love, gratitude, equanimity, and compassion“Trust that you make a difference, and that each one of us makes a difference.” – Jack KornfieldThis episode was recorded on 04/07/2025 for the Spirit Rock Meditation Center Monday Night Dharma Talk and Guided Meditation. “We're in this together, we can awaken together, and we can support our hearts, minds, and the beautiful world that we can be—it's in us as part of our imaginal cells.” – Jack KornfieldAbout Jack Kornfield:Jack Kornfield trained as a Buddhist monk in the monasteries of Thailand, India, and Burma, studying as a monk under the Buddhist master Ven. Ajahn Chah, as well as the Ven. Mahasi Sayadaw. He has taught meditation internationally since 1974 and is one of the key teachers to introduce Buddhist mindfulness practice to the West. Jack co-founded the Insight Meditation Society in Barre, Massachusetts, with fellow meditation teachers Sharon Salzberg and Joseph Goldstein and the Spirit Rock Center in Woodacre, California. His books have been translated into 20 languages and sold more than a million copies.Jack is currently offering a wonderful array of transformational online courses diving into crucial topics like Mindfulness Meditation Fundamentals, Walking the Eightfold Path, Opening the Heart of Forgiveness, Living Beautifully, Transforming Your Life Through Powerful Stories, and so much more. Sign up for an All Access Pass to explore Jack's entire course library. If you would like a year's worth of online meetups with Jack and fellow community, join The Year of Awakening: A Monthly Journey with Jack Kornfield.Stay up to date with Jack and his stream of fresh dharma offerings by visiting JackKornfield.com and signing up for his email teachings.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Gotta share some of the D-bag responses we got.

Stephen Grootes discusses with Peter Attard Montalto, Managing Director at Krutham, the potential implications of the US tariffs and the government's response, highlighting the need for strategic diplomatic and trade interventions to mitigate the impact on South Africa's economy. In other interviews, Consumer ninja, Wendy Knowler, chats about the potential pitfalls of cellphone contracts, particularly the steep penalties for early cancellation and the significant price hikes that can occur after the initial contract period ends, leaving customers facing much higher monthly subscription fees. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape. Thank you for listening to a podcast from The Money Show Listen live Primedia+ weekdays from 18:00 and 20:00 (SA Time) to The Money Show with Stephen Grootes broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/7QpH0jY or find all the catch-up podcasts here https://buff.ly/PlhvUVe Subscribe to The Money Show Daily Newsletter and the Weekly Business Wrap here https://buff.ly/v5mfetc The Money Show is brought to you by Absa Follow us on social media 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/CapeTalk 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/Radio702 CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567See omnystudio.com/listener for privacy information.

This is Part 5 of a 5 Part series on the evaluation of Reformed Theology, also referred to as Calvinism. We hope you will join us for this complete series.The age-old theological tension between God's sovereignty and human choice takes center stage in this illuminating episode. We dive deep into the most common criticisms of Reformed Theology and examine how its defenders respond to these challenges.What happens when someone claims that Reformed Theology makes God unrighteous? How do Reformed thinkers answer the charge that their theology renders human responsibility meaningless? We examine these provocative questions through quotes from prominent Reformed theologians like R.C. Sproul and A.A. Hodge, while carefully evaluating both sides of each argument.At the heart of this theological divide lies a fundamental question: does regeneration precede faith, or does faith precede regeneration? This seemingly technical distinction dramatically shapes how we understand salvation, God's character, and human responsibility. We explore biblical examples like Cornelius, Rahab, and Ruth that challenge simplistic theological formulations on both sides.The debate isn't merely academic—it touches on our deepest understanding of God's nature. Is God's love conditional or unconditional? Does His sovereignty mean He chooses some for salvation while leaving others without hope? Or does Scripture reveal a God who genuinely desires all people to be saved while respecting their freedom to reject Him?Whether you're a committed Calvinist, a convinced Arminian, a consistent Biblicist or simply curious about these theological traditions, this episode offers thoughtful, balanced perspectives that will deepen your understanding of these vital spiritual questions. Listen now to sharpen your theological thinking and gain fresh insights into how we can faithfully reason through Scripture.Support the showThank you for listening!! Please give us a five-star rating to help your podcast provider's algorithm spread RTTB among their listeners. You can find free study and leader resources at the following link - Resource Page - Reasoning Through the Bible Please prayerfully consider supporting RTTB to help us to continue providing content and free resources. You can do that at this link - Support RTTB - Reasoning Through the Bible May God Bless you!! - Glenn and Steve

ReferencesFront. Immunol., 22 February 2024Sec.Multiple Sclerosis and Neuroimmunology Volume 15 Arthritis Care Res (Hoboken). 2024 Aug 7;76(11):1451–1460Nat Immunol. 2024 Apr 8;25(5):778–789Lake, G 1972 "From the Beginning" ELP Trilogy lp.https://music.youtube.com/watch?v=hsJ9YXHqnr8&si=NoG1BHKOtrFNYItmJoel, B. 1972. "Scenes from An Italian Restaurant. Yhe Stranger lphttps://music.youtube.com/watch?v=rdAvFvDVXSk&si=_BhtdE6WKN2J80FV

This new Polycrisis series will explore the complex set of protracted, interconnected, and mutually reinforcing crises that disproportionately affect urban centers and urban populations, ranging from housing, democracy, transit, infrastructure, inequality, conflict, the environment, to health. What relevance do discussions of the “urban polycrisis” have for places in the Global South? This episode of the Urban Political Podcast examines how the urban polycrisis manifests in housing production and urban infrastructure, from an alleged fraying of the social fabric to continually increasing environmental damage and deeply entrenched inequality. Catalina Ortiz (University College London(, Thireshen Govender (UrbanWorks), and Katrin Hofer (ETH Zurich) convey their experiences with the constant state of polycrisis in places like Colombia and South Africa. Where the state cannot fully supply the conditions required for people to flourish – where people are long accustomed to taking the maintenance of everyday life into their own hands “insurgently.” Hosted by Lindsay Blair Howe (TU Munich), this episode highlights how researches and practitioners are conducting their work in spite of – or even by finding opportunities in – the constant state of crisis. These observations and actions may also provide solutions that the Global North will soon require. As of mid-2025, we have passed the critical 1.5 degrees benchmark, are enduring multiple megalomaniacs at the helm of national governments, and continue to use far more resources than our planet could ever supply. We may not have the tools or imagination to respond to these challenges like places where the polycrisis is the norm.

From the 2024 Society for Leukocyte Biology meeting, Cindy and Brianne talk with Darren Lee to discuss his career, how he got interested in immunology of the eye, and how his team visualizes immune responses of the eye in real time with the hope of better understanding autoimmune uveitis. Hosts: Cindy Leifer and Brianne Barker Guest: Darren Lee Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server The eye is an immunosuppressive environment (Adv Drug Delivery Rev 2023) Tregs control autoimmune uveitis (Sci Rep 2025) TIGIT, Tregs, and autoimmune uveitis (J Leuk Biol 2024) Society for Leukocyte Biology Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.

ReferencesFront. Immunol., 22 February 2024. Sec. Multiple Sclerosis and Neuroimmunology Volume 15 Nat Cell Biol. 2019 Mar; 21(3): 397–407.CELL 2006. Volume 126, Issue 3, 11 August Pages 503-514Valenti, D. 1971. "Dont Cry My Lady Love"https://music.youtube.com/watch?v=Aqt0yhGfC1s&si=fXpd1HifSgtEHtpbLennon/McCartney. 1966. "For No One"Revolver. lp.https://music.youtube.com/watch?v=ELlLIwhvknk&si=ZgDZXKn_UPC3RHBmMozart, WA. 1773. Symphony 25 in G Minorhttps://music.youtube.com/watch?v=707oHEGF6l8&si=rwJRSJ2CeYfYVIas

The second installment of the three-part podcast series features Karen Tynan, who co-chairs the Workplace Violence Prevention Practice Group, and guest speaker Dan Skoczylas as they continue their discussion of the Federal Bureau of Investigation's (FBI) 2024 report on “Active Shooter Incidents in the United States.” Karen (shareholder, Sacramento) and Dan, who is a workplace violence mitigation consultant, review the report's data on the duration of incidents and law enforcement response times and what these mean for employer training and preparedness. They also explore the role of security personnel and the importance of recognizing behavioral warning signs.

ReferencesGuerra. DJ. 2025. Unpublished LecturesFront. Immunol.,2024. 22 February Sec. Multiple Sclerosis and Neuroimmunology Volume 15 .Annals of Clinical & Laboratory Science.2022.vol. 52, no. 5 pp763-771.Mol Biosyst. 2014 Oct;10(10):2505-8. Frey/Henley. 1973. "Desperado" The Eagleshttps://music.youtube.com/playlist?list=OLAK5uy_k3UBMdBe0k-PWX6y1VCLJZVJogoUaKEco&si=9kkmSQG5xcdpbINRWelch, B 1973. "Emerald Eyes" Fleetwood Mac.Mystery to Me lp.https://music.youtube.com/watch?v=DnQM535xV-U&si=sRsNuXaEJ1A4VWPJ

07/06/2025 - Sunday Morning Message at Pinheads Family Entertainment Center in Fishers, IN

The second phase of the Covid Inquiry starts today, with vaccine mandates proving to be a hot topic. The hearings will be held in Auckland, available to watch online and will be chaired by KC Grant Illingworth. Phase two is focused on aspects of the Covid response like vaccine mandates, the approval process and vaccine safety. Illingworth told Heather du Plessis Allan that there are 31-thousand submissions, with a fair chunk focused on the mandates. He says there's a number of people who think the mandates protected them, and many others who have an opposite view. See omnystudio.com/listener for privacy information.

A few weeks ago I shared a client case study where they went from 600K to 1MM in sales per week by implementing one critical change in how they engage new paid leads in their business. This one shift allowed them to go from 30% connection to 80% connection rate on new leads. This week I am explaining exactly what they did to make that happen around Engaging, getting Responses and the Converting these leads into actual appointments.

In this episode, we delve into the complexities of global conflict with Hal Kempfer, a retired Marine Intelligence Officer and strategic risk expert. Covering critical issues such as the ongoing war in Ukraine and the geopolitical shifts in Siberia, we explore North Korea's involvement in Russia's military efforts and the implications of a potential arms shipment suspension from the U.S. We also examine historical tensions between Russia and China, particularly concerning Siberian territories. With insights into battlefield strategies, troop movements, and the broader impact on international relations.Takeaways:• North Korea's troop deployment to support Russia in Ukraine.• The ongoing summer offensive and heavy losses faced by Russia.• Ukraine's impact on Russian territory with deep strikes.• The suspension of U.S. arms shipments to Ukraine raises concerns.• Historical context of the Amur Annexation and its relevance today.• China's strategic interests in Siberia and potential territorial claims.• The implications of Russia's reliance on China amid military struggles.• Responses needed from the U.S. and allies concerning regional security. #GlobalConflict #WarInUkraine #NorthKorea #Russia #Geopolitics #ArmsShipments #China #Siberia #MilitaryStrategy #IntelligenceAnalysis #PublicSafety #InternationalRelations #HistoricalContext #AmurAnnexation #RiskAnalysis #MilitaryLosses #PoliticalTensions #DefenseStrategies #STRATPodcast #HalKempfer #MutualBroadcastingSystem #StrategicRiskAnalysis

Callers dropped their takes about what the Detroit Pistons should and shouldn't do this offseason. Take a listen to what Pistons fans are thinking... --Voicemail call in: (219) 413-9405Instagram: @TheRunPodcastFacebook: PodcastTheRunYouTube: The Run with Manny WilsonTheRunUSA.com

In this JCO Article Insights episode, host Peter Li summarizes "Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST" by Pérol et al, published April 03, 2025, followed by an interview with first author, Dr Maurice Pérol. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li: Welcome to this episode of JCO Article Insights. I am Dr. Peter Li, JCO's editorial fellow, and today I am joined by Dr. Maurice Pérol on “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” by Pérol et al. At the time of this recording, our guest has disclosures that will be linked in the transcript. Before we start our interview, I want to give our listeners a quick summary of the TRUST study. For those tuning in, the TRUST study is a phase II, single-arm, open-label, nonrandomized, multicenter trial looking at the efficacy and safety of a novel, next-generation ROS1 TKI, taletrectinib, in advanced ROS1-mutated non–small cell lung cancer. While a relatively rare mutation, the prevalence of ROS1 mutations ranges from 0.9% to 2.6% of patients, with a third of patients presenting with brain mets at diagnosis.Current FDA-approved therapies include crizotinib, entrectinib, and repotrectinib, which have varying degrees of efficacy, in-coming with trade-offs in CNS penetrance and safety with newer generations, particularly in the realm of neurological side effects, highlighting an unmet need in this arena. A total of 273 patients with advanced non–small cell lung cancer with confirmed ROS1 mutation were recruited for this study. 160 patients were TKI-naive, while 113 were TKI-experienced with either crizotinib or entrectinib. Patients with asymptomatic brain mets were also allowed to enroll. In the TKI-naive arm, the median age was 57, with 91% of patients having stage IV disease, 20% having no more than one cycle of chemo, and 23% having brain mets at baseline. In the TKI-experienced arm, the median age was 53, with 97% having stage IV disease, 37% having received prior chemo, and about 50% having brain mets. Furthermore, about 10% of the study population had received entrectinib, while more than 90% had received crizotinib. About 10% had a known G2032R acquired resistance mutation. Taletrectinib was dosed at 600 mg daily until disease progression or unacceptable toxicities. The primary endpoint was overall response rate, with secondary endpoints being disease control rate, duration of response, time to response, and progression-free survival. For those with brain mets, intracranial overall response rate and disease control rate were also assessed. Median follow-up time was about 21 months in both cohorts. In the TKI-naive cohort, the overall response rate was 89%, with 8 patients achieving a complete response. Disease control rate was 95%, with a median duration of response of 44.2 months. Time to treatment response was about 1.5 months. Median progression-free survival was 45.6 months, with 52.6% not having progressed at 3 years. While overall survival data were immature, 66% of patients were still alive at 3 years. In the pretreated cohort, overall response rate was 56%, with 5 patients achieving a complete response. Overall response rate was 53% for those who were crizotinib-pretreated and 80% for the entrectinib-pretreated patients. Disease control rate was 88%, and median duration of response was about 16.5 months. Time to treatment response was also 1.5 months, and median progression-free survival was 9.7 months. Median overall survival was not reached, but 77.5% of patients were still alive at 1 year. Responses were consistently seen across subgroup analyses. 17 TKI-naive and 32 TKI-pretreated patients had measurable brain mets. In the TKI-naive arm, intracranial overall response rate was 77%. Disease control rate was 88%, and duration of response was 15 months. In the TKI-pretreated arm, intracranial overall response was 66%, with one patient achieving complete response. The disease control rate was 94%, and duration of response was about a year. For the 13 patients who had a known G2032R mutation, a 62% response rate was noted. Most common treatment-related side effects were AST/ALT elevation, nausea, and vomiting, with most being grade 1 or 2. Most common neurological side effects were dizziness, dysgeusia, and headache. Again, most were grade 1. QTc prolongation is another important adverse event to note, occurring in about 18% of all patients. Discontinuation rate from treatment was only 7%. There were three treatment-related deaths in this study: one from hepatic failure, one from pneumonia in the naive arm, and one from liver dysfunction in the pretreated arm. Dr. Peter Li: Maurice, thank you so much for joining us today to talk about your paper. Would you mind just giving yourself a brief introduction to the listeners out there of who you are? Dr. Maurice Pérol: So, my name is Maurice Perol. I'm a thoracic oncologist working in the Cancer Center of Lyon in France. And I'm involved in clinical research in thoracic oncology. I've been involved for many years now. Dr. Peter Li: Okay. And for listeners out there, don't forget, he's also the primary author of the paper that we just talked about. So, Maurice, let's begin. Can you tell our listeners what is the significance of your study? Dr. Maurice Pérol: Well, the results of these two large phase II studies - TRUST-I, which has been conducted in China, and TRUST-II, which was a global, worldwide phase II study - so, the results place taletrectinib as the TKI with the most favorable efficacy-tolerability ratio of the available ROS1-targeting TKIs, especially in frontline therapy. And this is based on the response rate, which was very impressive, the CNS penetration with a great CNS activity, the duration of response with a compelling 45 months median PFS in frontline setting. The level of activity in pretreated patients after crizotinib or entrectinib was also impressive and similar to that of repotrectinib, for example, but with a more favorable neurological tolerance profile. The toxicity is mainly represented with grade 1 or 2 transaminase elevation, but without clinical symptoms, and GI toxicity, but mainly grade 1 and 2. The neurological toxicity is low, especially for dizziness, showing that taletrectinib spares TrKB in a large part. And finally, there is also a decrease in toxicity over time, especially for GI toxicity and liver toxicities, which allows a very long and a prolonged administration, which is very important in this setting. Dr. Peter Li: These are all excellent points. Can you tell the listeners if there are any limitations that we should be concerned about, about this study? Dr. Maurice Pérol: Sure. This data comes from single-arm phase II studies. So, this is not comparative data. And a phase III trial, which compares taletrectinib to crizotinib, is ongoing to evaluate the superiority of taletrectinib over the standard of care. Another limitation comes from the lack of systematic brain imaging at each tumor evaluation in patients without brain metastases at baseline, not allowing to assess the intracranial PFS in all patients, and which did not allow us to assess the CNS protective issue from taletrectinib, especially in patients without brain metastases at baseline. Dr. Peter Li: Another question that I have is, with this novel TKI now available, how would you recommend the sequencing of these drugs? Would you start with someone on an alternate TKI and then reserve taletrectinib second line or later? Or would you use it upfront? Or does it depend? Dr. Maurice Pérol: Well, it is a very important question, as we have now different available TKIs. Looking at the efficacy-toxicity balance, I would strongly favor the use of taletrectinib in frontline setting, in first line. The response rate, the CNS activity, the duration of response with a very compelling 45 months median PFS, and moreover, the good tolerance profile over time are strong arguments in favor of giving taletrectinib in frontline. Generally speaking, the use of the most active agent as frontline treatment in lung cancer depending on an oncogenic addiction is probably the best way to improve the patient's outcome. This is true for patients with EGFR mutation, for patients with ALK fusions, and this is probably also true for patients with ROS1 fusion. So, I would probably argue in favor of a frontline use of taletrectinib. Dr. Peter Li: Listeners are going to ask, well, if you use taletrectinib upfront, then what are you going to use second line once they progress? Dr. Maurice Pérol: Well, we have some new compounds which are under development today. For example, the NVL-520, which is a very interesting compound, which seems also to be active in case of resistance mutation. But I do think that we have to use the best-in-class TKI in frontline because, you know, the extension of PFS after acquired resistance you can obtain with a second-line TKI is always shorter than the benefit you can obtain by using the most active agent in frontline. And this is true for the majority of oncogenic addiction in lung cancer. Dr. Peter Li: That makes sense. I also noticed that cognitive impairment wasn't listed in the safety table. Is that not an issue that you've observed at all with taletrectinib, or is it still an issue but less so because, like you mentioned earlier, because of its higher selectivity? Dr. Maurice Pérol: Well, this is a good question because we have some ROS1-targeting TKIs like repotrectinib, entrectinib, and even lorlatinib, with some neurological adverse events and some cognitive issues. Taletrectinib is a very selective ROS1-targeting TKI, and it spares very well the TrKB, for example, explaining that we did not observe any cognitive impairment with taletrectinib in the TRUST study, showing also with the low level of other neurological adverse events, dizziness, dysgeusia, for example, the high selectivity of the compound and the preservation of TrKB. So, this is very important when you consider the long duration of treatment in those patients with ROS1 fusion. If you have to take a drug for more than 2, 3, or 4 years, of course, the neurological adverse events are very important, and they can clearly impair the quality of life. So, this is a very important point, the very low level of neurological toxicity of taletrectinib. Dr. Peter Li: And I think that goes to say why you would favor using it frontline as well compared to entrectinib or repotrectinib. Last question that we have for you is: well, what's next? You mentioned there's a phase III trial comparing it to crizotinib. I think one of the questions that a lot of us would have is: why not compare it to one of the newer agents as a comparator arm? Dr. Maurice Pérol: Well, this is a good question. Crizotinib remains the standard of care in many countries for ROS1-positive advanced non–small cell lung cancer outside of the US, especially in Europe, and in particular in patients who do not have brain metastases at diagnosis. Entrectinib has a better CNS penetration, but it did not achieve a better PFS than crizotinib in phase I/II trials, and clearly, it has a less favorable tolerance profile with weight gain, edema, and neurological adverse events. Repotrectinib has overall a level of activity which seems close to that of taletrectinib. So, it makes it difficult to consider a comparative trial that would, for example, test taletrectinib in comparison with repotrectinib because this kind of study would need a very large number of patients and a very late readout. Considering if you have a median PFS of more than 3 or 4 years, it would be very difficult to have results in before 4-5 years. So, from a pragmatic point of view, the comparison of taletrectinib to crizotinib is probably the best way to evaluate in a phase III setting the level of activity of taletrectinib, especially in the CNS, because this study will probably allow us to assess the CNS protective effect of the compound for patients without brain metastates at baseline. So, I think probably it's a pragmatic study that will allow us to confirm the high level of activity and the good tolerance profile of taletrectinib. Dr. Peter Li: Well, thank you, Maurice, so much for speaking about the JCO article, “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” and for all your valuable input today. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Message From Susan Hey everyone, it's Susan, and you're about to hear one of my training tips and tidbits. These are quick, actionable strategies to help you and your dog in everyday life or for dog sport. Often our short videos with tips are created from your most popular segments of podcast episodes. So, let's dive in!   The Truth About Over-Aroused Dogs And What Shapes Their Emotional Responses Ever had a moment when your dog's emotions felt bigger than everything else around them? I'm sharing the truth about over-aroused dogs and what shapes their emotional responses. When we understand what's behind those big reactions, we can better support our dogs and set them and ourselves up for success. Watch the full video at https://www.youtube.com/watch?v=06CyHsE-bEY

This morning, we talk about the Thomas Cole National Historic Site in Catskill and their new exhibition of artwork by Emily Cole, Thomas Cole's daughter. The exhibition — titled “Emily Cole: Ceramics, Flora & Contemporary Responses” — will include the largest display of original painted porcelain and works on paper by Emily Cole ever shown since the 19th century.Her work is being presented within the Cole family's historic home and studio alongside, and in conversation with, related works by eight, internationally celebrated, 21st-century artists.

For pride month, the girlies mount a defense against one of the largest threats to queer people today: transphobia. They trace the long history of trans existence and its erasure, unpack how moral panic is used to justify control, why transphobia exists on both the right and the left, and how the freedom to live outside the binary can liberate us from other systems of oppression. Digressions include: the highs and lows of plant parenthood, our no-phone summer so far, and a new candy shaking up the scene. This episode was produced by Julia Hava and Eliza McLamb and edited by Livi Burdette. Research assistance from Kylie Finnigan. To support the podcast on Patreon and access 50+ bonus episodes, mediasodes, zoom hangouts and more, visit patreon.com/binchtopia and become a patron today. RESOURCES: https://transharmreduction.org/ https://www.thetrevorproject.org/  https://translifeline.org/ https://transequality.org/  https://transgenderlawcenter.org https://pflag.org/get-support/ https://transreads.org/  https://www.elevatedaccess.org/ https://www.pointofpride.org/resource-library SOURCES: 2025 anti-trans bills tracker  A History of Transphobia in the Medical Establishment  A Lost Piece of Trans History  A systematic review of TERF behaviour online in relation to sociopsychological group dynamics Advancing Transgender Justice: Illuminating Trans Lives Behind and Beyond Bars  Anti-trans legislation has never been about protecting children' Anti-Trans Moral Panics Endanger All Young People Better mental health found among transgender people who started hormones as teens Beyond Gender: Indigenous Perspectives, Muxe  Beyond moral panic: how governments are ignoring centuries of trans history  Black on Both Sides: A Racial History of Trans Identity by C. Riley Snorton Clayman Conversations: Three scholars examine the TERF Industrial Complex Fact Sheet: Transgender Participation in Sports  Gender Identity in Weimar Germany  Gender-Affirming Hormone Therapy and Depressive Symptoms Among Transgender Adults   Impact of Ban on Gender-Affirming Care on Transgender Minors  India's Relationship with the Third Gender  Introduction: TERFs, Gender-Critical Movements, and Postfascist Feminisms  Mental health benefits associated with gender-affirming surgery Mental Health Outcomes in Transgender and Nonbinary Youths Receiving Gender-Affirming Care Marxism, moral panic and the war on trans people  “Moving Towards the Ugly” My Words to Victor Frankenstein by Susan Stryker Online Anti-LGBTQ Hate Terms Defined: “Transvestigation”  On Liking Women by Andrea Long-Chu Othering, peaking, populism and moral panics: The reactionary strategies of organised transphobia Responses to Janice G. Raymond's The Transsexual Empire The “Empire” Strikes Back: A Posttranssexual Manifesto The Epidemic of Violence Against the Transgender & Gender-Expansive Community in the U.S.  The Forgotten History of the World's First Trans Clinic How historians are documenting the lives of transgender people  The History of Two-Spirit Folks  The Institute of Sexology and the Erasure of Transgender History  The semi-sacred ‘third gender' of South Asia       The Supreme Court's incoherent new attack on trans rights, explained Theorist Susan Stryker on One of Her Most Groundbreaking Essays, 25 Years Later  The rise of anti-trans “radical” feminists, explained To protect gender-affirming care, we must learn from trans history Transgender History by Susan Stryker Transgender Lives in the Middle Ages through Art, Literature, and Medicine  TV and films have long taught audiences transphobia What science tells us about transgender athletes  Williams Institute at UCLA School of Law - More than 40% of transgender adults in the US have attempted suicide  Woman says she was brutally attacked in Carpentersville, Illinois because she's a lesbian

Episode 160 - Christian Responses to Christian Nationalism with Victor Nelson by Temple Beth Shalom

In this episode Trent reviews the ethics surrounding a recent case of keeping a brain-dead woman alive to save her unborn child as well as the monstrous responses to this case by pro-abortion advocates. New Symposium to Address Challenging Questions about Brain Death: https://www.ncbcenter.org/ncbc-news/brain-death-symposium https://braindeathintegritysymposium.com

Stories we're following this morning at Progress Texas:Latest on Donald Trump's attack on nuclear facilities in Iran: https://www.nytimes.com/2025/06/22/us/politics/trump-iran-decision-strikes.html...Responses from Texas Democratic U.S. Reps Lloyd Doggett, Greg Casar, Lizzie Fletcher, and Sylvia Garcia: https://www.khou.com/article/news/local/texas/texas-lawmakers-leaders-trump-iran/285-32881e5e-89ce-49ef-bd91-2795e3151ad6...Rep. Joaquin Castro: https://x.com/JoaquinCastrotx/status/1936625247827984825?t=W3viAqQkePA_BDDbdUMCzw&s=03...Rep. Julie Johnson: https://x.com/RepJasmine/status/1936589516283978011?t=oUJBI0mTXCogRIoPwFoGmw&s=03...Eight things to know about Trump's Iran attack, from Connecticut Senator Chris Murphy: https://www.chrismurphyct.com/p/8-things-you-should-know-about-trumps?utm_campaign=post&triedRedirect=trueGovernor Abbott has vetoed SB 3, Lt. Governor Dan Patrick's THC ban: https://www.texastribune.org/2025/06/22/texas-thc-ban-bill-greg-abbott-veto-senate-bill-3/?_bhlid=4937622fa4afb7b6d628185df1035b9f2279d7b7...Abbott has called a special session for a re-do on hemp regulation, and a revisiting of six other bills he vetoed: https://www.texastribune.org/2025/06/22/texas-governor-greg-abbott-special-session-veto-bills-thc-ban/...Abbott signed into law SB 10, the forcing of the display of the Ten Commandments in Texas classrooms, which is certain to face aggressive legal resistance: https://www.dallasnews.com/news/politics/2025/06/21/gov-abbott-signs-ten-commandments-bill-mandating-displays-in-texas-classrooms/...He also signed into law SB 11, which will allow local school boards to mandate prayer time in their districts: https://www.dallasnews.com/news/politics/2025/05/22/prayer-period-in-texas-public-schools-expected-to-reach-gov-abbott-for-approval/...And Abbott signed HB 229, the "Women's Bill Of Rights" that amounts to an erasure of trans Texans into law on Friday: https://klewtv.com/news/nation-world/gov-abbott-signs-womens-bill-of-rights-which-opponents-call-an-attack-on-trans-texansThe merch to match your progressive values awaits at our web store! Goodies at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://store.progresstexas.org/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.Thanks for listening! Find our web store and other ways to support our important work at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://progresstexas.org⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

This week on the show we feature an interview with two anarchists activists in southern California about the recent resistance to Federal-led immigration raids in Los Angeles and the wider region. Both guests speak about their experiences working in rapid response structures to immigration raids, to anti-homeless sweeps and other community needs over the years and how they've changed as conditions and technologies have changed. We talk about inviting and engaging new activists and some strategies that showed success. Some great writings from the streets can be found at Ediciones Ineditas: https://ineditas.noblogs.org/post/2025/06/18/fuck-i-c-e-city-wide-los-angeles-goes-up/ . ... . .. Featured Track: Bella Ciao by La Plebe from Brazo En Brazo

measure your progress with this video quiz

What do you think when you hear the word “church”? Responses vary from positive to negative, or even completely dismissive. If a building is what comes to mind, you may be surprised to learn what Scripture teaches. Listen to Truth For Life with Alistair Begg. ----------------------------------------- • Click here and look for "FROM THE SERMON" to stream or read the full message. • This program is part of the series‘The Basics of the Christian Faith' • Learn more about our current resource, request your copy with a donation of any amount. • You Give. God's Word Changes Lives. Daily teaching from Truth For Life relies on your prayer and financial support. Will you become a monthly donor today? Sign up at ‘ truthforlife.org/truthpartner.' Helpful Resources - Learn about God's salvation plan - Read our most recent articles - Subscribe to our daily devotional Follow Us YouTube | Instagram | Facebook | Twitter This listener-funded program features the clear, relevant Bible teaching of Alistair Begg. Today's program and nearly 3,000 messages can be streamed and shared for free at tfl.org thanks to the generous giving from monthly donors called Truthpartners. Learn more about this Gospel-sharing team or become one today. Thanks for listening to Truth For Life!